** Shares of Vitrolife VITR.ST rise ~10% after the Swedish
medical technology group's Q2 EBITDA more than doubles to SEK
273 million urn:newsml:reuters.com:*:nFWN2YW0XF
** VITR jumps to the top of the STOXX .STOXX index
** "Vitrolife continues to improve organic growth and
margins with good balance support from all regions and both
technology and consumables," Redeye analyst Johan Unnerus says
** Unnerus adds that the improved gross margins in Q2 are
"essential after a softer period"
** Stock down 51.6% so far this year
(Reporting by Jacob Rasmussen)
((jacob.rasmussen@thomsonreuters.com))